Bleeding and Thrombotic Risk Prediction in Acute Leukemia: Clinical Utility of the Siriraj Acute Myeloid/Lymphoblastic Leukemia (SiAML) Score Versus Established Hemostatic Tools

Launched by ASSIUT UNIVERSITY · Aug 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying ways to better predict the risk of bleeding and blood clots in people newly diagnosed with acute leukemia, a type of blood cancer. Bleeding and clotting problems are common and serious complications in acute leukemia, but it’s hard for doctors to know which patients are most at risk. This study will compare several different scoring systems, including a new one called the SiAML score, to see which best predicts these risks across all types of acute leukemia. The goal is to help doctors identify high-risk patients early so they can tailor treatment and improve care.

The trial is open to adults newly diagnosed with acute leukemia, including acute lymphoblastic leukemia (ALL), acute promyelocytic leukemia (APL), and acute myeloid leukemia (AML). People with a history of certain blood clotting disorders, those who have taken blood-thinning medications before their leukemia diagnosis, or those with bleeding problems from other causes won’t be eligible. Participants will be followed closely to collect information about bleeding and clotting events, helping researchers test and improve the scoring tools. The study is designed to be thorough and accurate, aiming to provide better guidance for managing these serious complications in leukemia patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Newly diagnosed patients with acute leukemia, including: Acute lymphoblastic leukemia (ALL) Acute promyelocytic leukemia (APL) Acute myeloid leukemia (AML)
• Exclusion Criteria:
• • • Patients with a known history of familial thrombophilia.
• • Patients who received antiplatelet or anticoagulant agents prior to the diagnosis of acute leukemia.
• • Patients who complained of bleeding related to any coagulation disorders